

## *MolMed: organizational structure optimization and further corporate governance strengthening*

Milan, January 29, 2015 – The Board of Directors of MolMed S.p.A. (MLM.MI), meeting today under the chairmanship of Professor Claudio Bordignon, approved the establishment of a Nomination Committee and the renewal of the Company's organizational structure, advancing in the Corporate Governance changing process, began last December with the appointment of Dr Palmisano as Chief Executive Officer.

As regards the corporate governance, being the Board of Directors term close to expiry, it was considered appropriate to establish a Nomination Committee, consolidated with the Remuneration Committee, mainly consisted of independent members, which could express opinions on the next Directors' ideal characteristics, providing the Company with the best possible management skills to face the forthcoming new phase of development. Therefore, the role of the Remuneration and Nomination Committee, whose members are Raffaella Ruggiero, Sabina Grossi e Didier Trono, will be of advisory and consulting to the Board of Directors regarding the optimal composition of the Board, identifying and indicating the professional profiles that can facilitate its effective functioning.

The organizational structure renewal today approved is aimed at improving the decision-making processes in terms of effectiveness and efficacy, at gaining greater organizational clarity, and therefore stronger offices accountability, and at putting more focus on the core activities for the future development of the Company. The project provides for the structure simplification, the merger of some support functions, to achieve the highest synergies, and for internal skills exploitation.

The new organizational structure of the Company, immediately effective, provides for the establishment of a single General Manager office, hold by Dr G. Paolo Rizzardi, and for the removal of the General Manager office for Corporate Governance & Administration, whose main functions directly report to the CEO.

*"Today structural change," said Riccardo Palmisano, CEO of MolMed S.p.A., "will provide MolMed with a simpler organization, more focused on the priorities which our company is getting ready to tackle. Thanks to more responsive and faster internal processes, combined with the enhancement of our talents, we will be able to make increasingly targeted decisions in order to accelerate the integration process between science and market, while ensuring the continuity of Company excellence."*

---

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

### *About MolMed*

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially

---

## **FROM GENES TO THERAPY**

### **MOLMED S.p.A.**

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325  
info@molmed.com - [www.molmed.com](http://www.molmed.com)

Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the tumour mass, currently investigated in a broad clinical programme; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed has its headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

*For further information:*

**Laura Villa**

**Investor Relations Director**

MolMed S.p.A.

telefono: +39 02 21277.205

fax: +39 02 21277.325

e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**Press agent**

**Federico Ferrari**

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: [ferrari@secrp.it](mailto:ferrari@secrp.it)

**DISCLAIMER**

*This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A..*